TrialThe Lancet. Oncology2024

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.

Loren K Mell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.